Trial Profile
A phase 3 trial of cytisine as a smoking cessation aid
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Aug 2017
Price :
$35
*
At a glance
- Drugs Cytisinicline (Primary) ; Nicotine replacement therapy
- Indications Smoking withdrawal
- Focus Therapeutic Use
- Acronyms CASCAID
- 10 Aug 2017 According to an Achieve Life Sciences media release, this trial was conceived by Dr. Natalie Walker, National Institute for Health Innovation, University of Auckland and funded by the Health Research Council of New Zealand.
- 08 Mar 2017 According to an OncoGenex Pharmaceuticals media release, this trial was conducted by Dr. Walker.
- 28 Jul 2015 New trial record